Toronto, Ontario (Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc. finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Global Drug Delivery Systems (DDS) Markets 2021-2027 - Increasing R&D Expenditures of Innovator Companies and the Trend of Patent Portfolio Expansion prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(1)
Vancouver, British Columbia (Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ( iCo or the Company ) is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the Exchange ) of iCo s proposed business combination (the Transaction ) with Satellos Bioscience Inc. ( Satellos ).
The Company has filed an information circular on SEDAR (the Circular ) that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of the special meeting of shareholders of the Company to approve the Transaction, in accordance with the rules of the Exchange. The shareholder meeting is more fully described in the Circular.